

519,430

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number  
**WO 2004/003565 A2**

(51) International Patent Classification<sup>7</sup>: G01N 33/68

JAUSLIN, Matthias [CH/CH]; Klingelberstrasse 33,  
CH-4056 Basel (CH). SCHOUmacher, Fabrice  
[CH/CH]; 20, rue Laparade, F-68440 Eschentzwiller (FR).

(21) International Application Number:  
PCT/EP2003/007006

(22) International Filing Date: 1 July 2003 (01.07.2003)

(74) Agent: GRÜNECKER, KINKELDEY, STOCKMAIR  
& SCHWANHÄUSSER; Maximilianstrasse 58, 80538  
München (DE).

(25) Filing Language: English

(81) Designated States (*national*): CA, US.

(26) Publication Language: English

(30) Priority Data:  
02014542.1 1 July 2002 (01.07.2002) EP

(84) Designated States (*regional*): European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): MY-  
OCONTRACT LTD [CH/CH]; Hammerstrasse 25,  
CH-4410 Listal (CH).

Published:  
— without international search report and to be republished  
upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MEIER, Thomas  
[CH/CH]; Wintergasse 10, CH-5065 Basel (CH).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: A SCREENING METHOD AND COMPOUNDS FOR TREATING FRIEDREICH ATAXIA

(57) Abstract: The present invention relates to a method for identifying and/or validating candidate substances for the treatment of Friedreich Ataxia (FRDA). Furthermore, the present invention relates to the use of selenium, Ebselen and Glutathione peroxidase (GPX) mimetics for the preparation of a medicament for the treatment of FRDA. Another aspect of the present invention relates to the use of cells with reduced frataxin expression for identifying and/or validating candidate substances for the treatment of Friedreich Ataxia.

WO 2004/003565 A2